209 related articles for article (PubMed ID: 10091774)
1. Surveillance of patients to detect recurrent thyroid carcinoma.
Grigsby PW; Baglan K; Siegel BA
Cancer; 1999 Feb; 85(4):945-51. PubMed ID: 10091774
[TBL] [Abstract][Full Text] [Related]
2. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
3. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
5. Routine 201Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact.
Hsu CC; Chen YW; Huang YF; Chuang YW
Nucl Med Commun; 2007 Sep; 28(9):681-7. PubMed ID: 17667746
[TBL] [Abstract][Full Text] [Related]
6. The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Siddiqi A; Foley RR; Britton KE; Sibtain A; Plowman PN; Grossman AB; Monson JP; Besser GM
Clin Endocrinol (Oxf); 2001 Oct; 55(4):515-21. PubMed ID: 11678835
[TBL] [Abstract][Full Text] [Related]
7. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
Gerard SK; Dam HQ
Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
[No Abstract] [Full Text] [Related]
8. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
9. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
10. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
12. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma.
Travagli JP; Cailleux AF; Ricard M; Baudin E; Caillou B; Parmentier C; Schlumberger M
J Clin Endocrinol Metab; 1998 Aug; 83(8):2675-80. PubMed ID: 9709930
[TBL] [Abstract][Full Text] [Related]
13. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma.
Lindegaard MW; Paus E; Høie J; Kullman G; Stenwig AE
Acta Chir Scand; 1988 Feb; 154(2):141-5. PubMed ID: 3354295
[TBL] [Abstract][Full Text] [Related]
14. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
15. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.
Shankar LK; Yamamoto AJ; Alavi A; Mandel SJ
J Nucl Med; 2002 Jan; 43(1):72-6. PubMed ID: 11801706
[TBL] [Abstract][Full Text] [Related]
17. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
18. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.
Almeida-Filho P; Ravizzini GC; Almeida C; Borges-Neto S
Clin Nucl Med; 2000 Jun; 25(6):443-6. PubMed ID: 10836693
[TBL] [Abstract][Full Text] [Related]
19. [Application of recombinant human TSH in the diagnostic protocol of differentiated thyroid carcinoma].
Jiménez-Hoyuela García JM; García Almeida JM; Delgado García A; Aguilar Fernández I; Martínez del Valle Torres MD; Ortega Lozano S; Rebollo Aguirre A; Mancha Doblas I; Pinzón Martín JL; Picón César MJ; Zamorano Vázquez D
Rev Esp Med Nucl; 2005; 24(3):152-60. PubMed ID: 15847782
[TBL] [Abstract][Full Text] [Related]
20. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
